Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Gynecol Oncol. 2016 Jul 19;143(1):143–151. doi: 10.1016/j.ygyno.2016.07.088

Figure 4. Panobinostat alone and combined with olaparib reduces HR repair in HR-proficient ovarian cancer cells.

Figure 4

A) The percentage of OVCAR-3 and SKOV-3 cells showing co-expression of RAD51 and pH2AX (positive was >5 foci). Cells were pre-treated with 0.5µM cisplatin (6h), then effects of the panobinostat pre-treatment (25nM; 24h)/panobinostat (25nM; 24h) and olaparib (10µM) co-treatment combination regimen (24h) determined by IF. B) IF analysis of GFP expression in cells co-transfected with pDRGFP and I-Sce1 plasmids (both 1µg), then treated with panobinostat and/or olaparib as above. At least 100 cells were counted in 3 independent fields. Values in A) and B) are mean+SD for 3 independent experiments. * p<0.01 compared to vehicle; ap<0.01 relative to olaparib alone, bp<0.01 relative to panobinostat alone, Student’s t test. C) Representative images of GFP-positive SKOV-3 cells (green) and DAPI-stained nuclei (blue). Scale bars are 20µm.